Travere Therapeutics to Report First Quarter 2023 Financial Results
Travere Therapeutics (NASDAQ: TVTX) is set to release its first quarter 2023 financial results on May 4, 2023, following the close of U.S. markets. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on its business. Interested parties can access the information on the Investor page of Travere’s website. Travere Therapeutics focuses on developing therapies for rare diseases, emphasizing its commitment to supporting patients and families facing these challenges. This upcoming earnings release may provide insights into the company’s financial health and strategic direction, crucial for stakeholders and investors.
- Upcoming conference call indicates transparency and engagement with investors.
- None.
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
| Investors: Naomi Eichenbaum Vice President, Investor Relations 888-969-7879 IR@travere.com | Media: Nivi Nehra Vice President, Corporate Communications 888-969-7879 mediarelations@travere.com |
FAQ
When will Travere Therapeutics report its first quarter 2023 financial results?
What time is the conference call for Travere Therapeutics' financial results?
Where can I find the webcast for Travere Therapeutics' financial call?
What is the stock symbol for Travere Therapeutics?
